‌

US Patent 11858995 Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia

Patent 11858995 was granted and assigned to Genmab A/S on January, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Brian Elliott0

Christopher W. L. Chiu0

Jenny Jianlin Chen0

Esther C. W. Breij0

Maria N. Jure-Kunkel0

Tahamtan Ahmadi0

Ida Hiemstra0

Date of Patent

January 2, 2024

0

Patent Application Number

175599350

Date Filed

December 22, 2021

0

Patent Citations

US Patent 9150663 Heterodimeric antibody Fc-containing proteins and methods for production thereof

0

US Patent 9212230 Bispecific antibodies and methods for production thereof

0

US Patent 10273227 C5-anilinoquinazoline compounds and their use in treating cancer

0

US Patent 10344050 Production of heterodimeric proteins

0

US Patent 10407501 Humanized or chimeric CD3 antibodies

0

US Patent 10465006 Humanized or chimeric CD3 antibodies

0

US Patent 10544220 Bispecific antibodies against CD3 and CD20

0

US Patent 10590206 Inert format

0

...

Patent Primary Examiner

Zachary S Skelding

0

Patent abstract

Provided are methods of clinical treatment of chronic lymphoblastic leukemia (CLL) in human subjects using a bispecific antibody which binds to CD3 and CD20.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11858995 Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.